Submission Details

Submitter:

Classification:
Definitive
GENCC:100001
Gene:
Disease:
Tatton-Brown-Rahman overgrowth syndrome
Mode Of Inheritance:
Autosomal dominant
Evaluated Date:
06/08/2023
Evidence/Notes:

DNMT3A encodes one of a family of DNA methyltransferases that catalyze the methylation of cytosine residues to 5-methylcytosine.DNMT3A variants were first reported in relation to autosomal dominant Tatton-Brown-Rahman syndrome in 2014 (Tatton Brown et al., PMID: 24614070). Tatton-Brown-Rahman syndrome (TBRS) is characterized by tall stature and macrocephaly >2 standard deviations above the mean for age and sex, increased weight/obesity, intellectual disability that ranges from mild to severe, joint hypermobility, hypotonia, autism spectrum/psychiatric issues, kyphoscoliosis, and seizures. Less common reported features include cryptorchidism, cardiovascular disease, ventriculomegaly, Chiari malformation, and acute myeloid leukemia. Probands have subtle dysmorphic features, including round face with coarse features, thick horizontal low-set eyebrows, narrow palpebral fissures, and prominent upper incisors. The facial gestalt is most apparent in adolescent years. Variants in DNMT3A are also implicated in a condition called Heyn-Sproul-Jackson Syndrome which presents with reciprocal phenotypes from TBRS such as extreme pre- and post-natal proportionate growth delay with microcephaly. While haploinsufficiency is believed to be the mechanism behind the Tatton-Brown-Rahman syndrome phenotype, the two variants currently reported in individuals with clinical diagnosis of Heyn-Sproul-Jackson are thought to be acting via a gain of function mechanism (PMID:30478443). The split curation for Heyn-Sproul-Jackson overgrowth syndrome is assessed separately.

Ten variants (missense, deletion, truncating) reported in ten probands in two publications (PMIDs: 24614070, 29900417) are included in this curation. However, recurrent variants have been reported in 11 unrelated TBRS individuals (PMID:29900417). Nearly all reported probands have de novo variants, but there are rare familial cases. For example, one paper described a missense variant transmitted from an unaffected mosaic parent (PMID: 27701732), and a separate publication reported a splice site variant in a proband, sibling, and parent (PMID: 28449304). Several inherited cases are also reported in the Brain Gene Registry (braingeneregistry.wustl.edu); a mother, daughter and son with TBRS phenotype have c.2711C>T, p.Pro904Leu variant, which is previously published in literature. This variant is also detected in 7 year old female whose mother was found to have 19.38% mosaicism. The variants identified in these individuals are not formally documented in this curation due to technical limitations, but they are available in ClinVar (ClinVar SCVs: SCV000491304.1, SCV001250294.15, SCV002107389.2). Of special note, somatic variants in DNMT3A are reported with clonal hematopoiesis and sporadic hematologic malignancies; therefore are over represented in population databases derived from peripheral blood samples in the aging population (PMID: 28229513). The Arg882 residue is the most common site of somatic DNMT3A variants and has also been reported in individuals with TBRS (PMID: 28941052); therefore, increasing malignancy risk for some TBRS cases. While more evidence is available in the literature, the maximum score for genetic evidence (12 points) has been reached.

Currently, there is no experimental evidence to support this gene-disease relationship.

In summary, there is definitive evidence to support the relationship between DNMT3A and autosomal dominant Tatton-Brown-Rahman Syndrome. The classification was approved by the Intellectual Disability and Autism Gene Curation Expert Panel on June 8, 2023 (SOP 9).

PubMed IDs:
24614070 29900417
Public Report:
Assertion Criteria:
Submitter Submitted Date:
12/05/2025

The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.